XML 99 R85.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 21, 2023
Jun. 26, 2022
Jul. 31, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Stock based compensation       $ 108,297   $ 216,741   $ 323,957  
Payment of additional tax           99,644   99,644  
Description for advisory agreement     As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023            
Stock-based compensation expense           680,389 $ 104,869 577,931 $ 24,401
Compensation for non-pecuniary damage amounting               21,744  
General and administrative expenses               164,859  
Four Third Party Consultants [Member]                  
Awarded shares 970,000                
Awarded share value $ 999,100                
Phase 1 [Member]                  
Project cost   $ 838,450              
Phase 2 [Member]                  
Project cost   $ 907,084              
National Medicines Agency [Member] | General and administrative expenses [Member]                  
Stock based compensation       $ 231,750 $ 0 463,500 $ 0 77,250  
Imposed fine           $ 16,214   16,214  
Stock-based compensation expense               $ 77,250